Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746. NB-4746 is believed to be a first-in-class, oral, brain-penetrant, neuroprotective SARM1…
Click here to view original post